"Sirukumab (Rheumatoid Arthritis) Forecast and Market Analysis" - New Market Report

Fast Market Research recommends "Sirukumab (Rheumatoid Arthritis) Forecast and Market Analysis" from GlobalData, now available

Logo

Boston, MA -- (SBWire) -- 01/22/2013 --GlobalData has released its new PharmaPoint Drug Evaluation report, Sirukumab (Rheumatoid Arthritis) Forecast and Market Analysis. The RA market is currently very dynamic, with the November 6, 2012 FDA approval of Pfizer's Xeljanz (tofacitinib) and novel oral therapies awaiting approval such as: Eli Lilly's anti-BAFF, tabalumab and JAK1,2 inhibitor, baricitinib, and Rigel/AZ's SYK inhibitor, fostamatinib. These compounds will challenge the current biologics in the attempt to dislodge the stronghold of the TNF inhibitors, if their safety and efficacy profiles are proven once they enter the market.

GSK and J&J are collaborating on sirukumab, a subcutaneous, human mAb, IL-6 inhibitor. Recently, it was announced that this drug will be entering into two Phase III studies: SIRROUND-T and SIRROUND-D. SIRROUND-T will recruit 990 patients with active RA who have had anti-TNF therapy and commence in global trials including the US, Australia, Germany, and Japan. SIRROUND-D will include 1,500 patients with active RA who have used MTX. This study will be hosted in clinical trial sites globally including the US, India, and Japan.

View Full Report Details and Table of Contents

Scope

- Overview of RA, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Sirukumab including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Sirukumab in six countries from 2011 to 2022.
- Sales information covered for the US, France, Germany, the UK, Italy and Spain.

Reasons to Get this Report

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for rheumatoid arthritis.
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Sirukumab performance
- Obtain sales forecast for Sirukumab from 2011 to 2022 in (the US, France, Germany, the UK, Italy and Spain)

About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

- PharmaPoint: Rheumatoid Arthritis- Spain Drug Forecast and Market Analysis Event-Driven Update
- PharmaPoint: Rheumatoid Arthritis- Germany Drug Forecast and Market Analysis Event-Driven Update
- PharmaPoint: Rheumatoid Arthritis- United States Drug Forecast and Market Analysis Event-Driven Update
- PharmaPoint: Rheumatoid Arthritis- France Drug Forecast and Market Analysis Event-Driven Update
- PharmaPoint: Rheumatoid Arthritis- United Kingdom Drug Forecast and Market Analysis Event-Driven Update
- PharmaPoint: Rheumatoid Arthritis- Italy Drug Forecast and Market Analysis Event-Driven Update
- Rheumatoid Arthritis Therapeutics- Pipeline Assessment and Market Forecasts to 2018
- PharmaPoint: Rheumatoid Arthritis- Japan Drug Forecast and Market Analysis Event-Driven Update
- PharmaPoint: Rheumatoid Arthritis- Australia Drug Forecast and Market Analysis Event-Driven Update
- PharmaPoint: Rheumatoid Arthritis- China Drug Forecast and Market Analysis Event-Driven Update

Media Relations Contact

Bill Thompson
Director of Marketing
800-844-8156
http://www.fastmr.com

View this press release online at: http://rwire.com/198405